Biotech Values

[DewDiligence]

PFE figures to generate ~$5B in incremental revenue from the settlement (assuming that the ‘893 patent was the only one that would’ve held up). Since the incremental revenue is mostly in the US, the settlement will assure that PFE has sufficient US funds to pay the outsized dividend (#msg-29765590) without repatriating cash from its foreign subsidiaries.